Search research articles
Contact Us
Filters
Showing results (91-100 of 101) with videos related to
Page
of 11
Sort By:
American Journal of Hematology
|
January 26, 2025
NOTCH1 Mutations Are Associated With Therapy-Resistance in Patients With B-Cell Lymphoma Treated With CD20xCD3 Bispecific Antibodies
Emil R Kyvsgaard, Morten Grauslund, Lene Sjø, et al.
Blood Neoplasia
|
August 14, 2025
Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study
Trine Trab, Iman Chanchiri, Ahmed Ludvigsen Al-Mashhadi, et al.
Blood
|
November 19, 2005
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis
Peter J Campbell, Martin Griesshammer, Konstanze Döhner, et al.
Blood Advances
|
May 8, 2020
Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis
Sirpa Leppä, Judit Jørgensen, Anne Tierens, et al.
Haematologica
|
October 15, 2020
Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study
Anders Lindholm Sørensen, Stine Ulrik Mikkelsen, Trine Alma Knudsen, et al.
Leukemia
|
November 25, 2018
JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation
Julia Czech, Sabrina Cordua, Barbora Weinbergerova, et al.
British Journal of Haematology
|
November 27, 2023
Real-world outcomes following third or subsequent lines of therapy: A Danish population-based study on 189 patients with relapsed/refractory large B-cell lymphomas
Ahmed Ludvigsen Al-Mashhadi, Lasse Hjort Jakobsen, Peter Brown, et al.
Bone Marrow Transplantation
|
December 17, 2025
Current capacity and gaps in viral vector manufacturing: a survey of centers associated with CTIWP of EBMT, NXTGEN-hightech, DARE-NL, T2EVOLVE, and GoCART coalition
Ganesh Ramesh, Zsolt Sebestyen, Anil Kumar Deshantri, et al.
Blood Advances
|
September 10, 2021
Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses
Trine Alma Knudsen, Vibe Skov, Kristen Stevenson, et al.
Science Translational Medicine
|
June 15, 2022
Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine
Mathieu Gigoux, Morten O Holmström, Roberta Zappasodi, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 101) with videos related to
Sort By:
Page
of 11
American Journal of Hematology
|
January 26, 2025
NOTCH1 Mutations Are Associated With Therapy-Resistance in Patients With B-Cell Lymphoma Treated With CD20xCD3 Bispecific Antibodies
Emil R Kyvsgaard, Morten Grauslund, Lene Sjø, et al.
Blood Neoplasia
|
August 14, 2025
Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study
Trine Trab, Iman Chanchiri, Ahmed Ludvigsen Al-Mashhadi, et al.
Blood
|
November 19, 2005
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis
Peter J Campbell, Martin Griesshammer, Konstanze Döhner, et al.
Blood Advances
|
May 8, 2020
Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis
Sirpa Leppä, Judit Jørgensen, Anne Tierens, et al.
Haematologica
|
October 15, 2020
Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study
Anders Lindholm Sørensen, Stine Ulrik Mikkelsen, Trine Alma Knudsen, et al.
Leukemia
|
November 25, 2018
JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation
Julia Czech, Sabrina Cordua, Barbora Weinbergerova, et al.
British Journal of Haematology
|
November 27, 2023
Real-world outcomes following third or subsequent lines of therapy: A Danish population-based study on 189 patients with relapsed/refractory large B-cell lymphomas
Ahmed Ludvigsen Al-Mashhadi, Lasse Hjort Jakobsen, Peter Brown, et al.
Bone Marrow Transplantation
|
December 17, 2025
Current capacity and gaps in viral vector manufacturing: a survey of centers associated with CTIWP of EBMT, NXTGEN-hightech, DARE-NL, T2EVOLVE, and GoCART coalition
Ganesh Ramesh, Zsolt Sebestyen, Anil Kumar Deshantri, et al.
Blood Advances
|
September 10, 2021
Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses
Trine Alma Knudsen, Vibe Skov, Kristen Stevenson, et al.
Science Translational Medicine
|
June 15, 2022
Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine
Mathieu Gigoux, Morten O Holmström, Roberta Zappasodi, et al.
Page
of 11